Advanced search
Publication Cover
Leukemia & Lymphoma Volume 63, 2022 - Issue 7
Submit an article Journal homepage
290
Views
0
CrossRef citations to date
0
Altmetric
Letters to Editor

A phase I study of rituximab and buparlisib in patients with relapsed or refractory indolent non-Hodgkin lymphoma

David A. Bonda Department of Internal Medicine, Division of Hematology b. Department of Hematology and Medical OncologyORCID Iconhttps://orcid.org/0000-0003-0773-1829
ORCID Icon,
Ying Huanga Department of Internal Medicine, Division of Hematology b. Department of Hematology and Medical Oncology
,
Beth A. Christiana Department of Internal Medicine, Division of Hematology b. Department of Hematology and Medical Oncology
,
Samantha Jaglowskia Department of Internal Medicine, Division of Hematology b. Department of Hematology and Medical OncologyORCID Iconhttps://orcid.org/0000-0002-4335-2554
ORCID Icon,
Don Bensona Department of Internal Medicine, Division of Hematology b. Department of Hematology and Medical Oncology
,
Lapo Alinaria Department of Internal Medicine, Division of Hematology b. Department of Hematology and Medical Oncology
,
Robert A. Baiocchia Department of Internal Medicine, Division of Hematology b. Department of Hematology and Medical Oncology
,
Jonathon B. Cohenb Emory University, Atlanta, GA, USA
,
Kristie A. Bluma Department of Internal Medicine, Division of Hematology b. Department of Hematology and Medical Oncology;b Emory University, Atlanta, GA, USA
&
Kami J. Maddocksa Department of Internal Medicine, Division of Hematology b. Department of Hematology and Medical OncologyCorrespondence[email protected]
 show all
Pages 1750-1753 | Received 19 May 2021, Accepted 22 Jan 2022, Published online: 06 Feb 2022
 
Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days
Click to increase image sizeClick to decrease image sizeFree first page

Disclosure statement

DB has consulted for Sea Gen and Kite/Gilead. BC has received research funding from Acerta, Celgene, Genentech, Triphase, MorphoSys, and Merck and has consulted for Verastem, Sea Gen, Genentech, and Astra Zeneca. SJ has received research funding from Gilead, Novartis, and Unum and has consulted for Bristol Myers Squibb, Gilead, and Novartis. JC has received research funding from Janssen, Novartis, TG Therapeutics, Astra Zeneca, Genentech, and Gilead and has consulted for Genentech, Bristol Myers Squibb, Novartis, Astra Zeneca, Loxo, and Sea Gen. KM has received research funding from Novartis, Bristol Myers Squibb, and Pharmacyclics and has consulted for Morphosys, ADC Therapeutics, Astra Zeneca, Beigene, Celgene, Gilead, and Sea Gen. All other authors declare no competing interests.

Log in via your institution

Access through your institution

Log in to Taylor & Francis Online

Restore content access

Restore content access for purchases made as guest
Purchase options * Save for later

PDF download + Online access

  • 48 hours access to article PDF & online version
  • Article PDF can be downloaded
  • Article PDF can be printed
USD 65.00 Add to cart

Issue Purchase

  • 30 days online access to complete issue
  • Article PDFs can be downloaded
  • Article PDFs can be printed
USD 1,065.00 Add to cart

* Local tax will be added as applicable

Related Research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.